NCT06791395

Brief Summary

Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related death worldwide. Colonoscopy is considered the preferred method of screening for colorectal cancer, and early and resection detection of colorectal neoplastic lesions can significantly reduce colorectal cancer morbidity and mortality. In order to improve the diagnostic accuracy of endoscopy for colorectal lesions, many endoscopic techniques, such as image-enhanced endoscopy, including narrow band imaging (narrow-band imaging, NBI), magnifying endoscopy, pigment endoscopy, confocal laser endoscopy, and endocytoscopy(EC), are applied clinically. However, with the increasing number of endoscopic resection, the costs associated with the pathological diagnosis of endoscopic resection and resection specimens increase year by year. In clinical practice, some non-neoplastic colorectal lesions may not require resection, so it is important to identify the nature of the lesion during colonoscopy. Leveraging deep neural networks, AI systems support both computer-aided detection (CADe) and computer-aided classification (CADx). CADe specifically focuses on identifying polyps in colonoscopy, with the goal of reducing adenoma miss rates. Hovever, CADx can predict the pathology of the lesion based on the surface condition of the lesion. Endocytoscopy is a kind of ultra-high magnification endoscopy. But it is not something that can be easily mastered by endoscopic doctors. The investigators have previously developed an artificial intelligence system that can assist in endocytoscopy. The investigators plan to conduct a prospective, multicenter clinical trial to verify the accuracy of this CADx in predicting the histological characteristics of colorectal lesions during real-time endocytoscopy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
570

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2025

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 20, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 24, 2025

Completed
12 days until next milestone

Study Start

First participant enrolled

February 5, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 29, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 29, 2025

Completed
Last Updated

April 13, 2026

Status Verified

April 1, 2026

Enrollment Period

11 months

First QC Date

January 20, 2025

Last Update Submit

April 8, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • To evaluate the diagnostic performance of the CAD-stained in diagnosing neoplastic lesions in a clinical setting.

    The diagnostic performance will be calculated for comparison with final histology as the gold standard for diagnosis

    11 months

Secondary Outcomes (4)

  • To evaluate the diagnostic performance of the CAD-NBI in diagnosing neoplastic lesions in a clinical setting.

    11 months

  • To compare the diagnostic performance of CAD-NBI and CAD-stained in colorectal neoplastic lesions different colorectal lesions.

    11 months

  • To evaluate the diagnostic performance of CAD-NBI and CAD-stained in the diagnosis of neoplastic DRSPs with high confidence

    11 months

  • To evaluate the agreement of post-polypectomy surveillance intervals based on CAD-NBI and CAD-stained predictions with histopathological diagnosis

    11 months

Study Arms (1)

Patients with one or more colorectao lesion detected

During colonoscopy, the endoscopist inspect for the presence of colorectal lesions as per routine clinical practice with the CADx turned off. When a colorectal lesion is encountered, the endoscopist will make a prediction on the histology based on the endoscopic diagnosis. Following this, the CADx will be triggered and display the endoscopic image captured by the endoscopist. and the endoscopist will take note of the CADx prediction for the same image. In addition, other lesion features such as the size and location will be recorded, which is similar to what is performed in routine clinical practice. The lesion will be endoscopic resected or surgery and sent for pathological examination, which will form the "gold standard" for the diagnosis of polyp histology.

Diagnostic Test: Computer-aided diagnosis (CADx) support tool

Interventions

The CADx support tool will display the prediction results when the endoscopists press the keys on the fixed keyboard. This is performed after the endoscopists first makes an optical prediction of colorectal lesion histology using endocytoscopy as described. The CADx support tool will make a prediction of colorectal lesion histology.

Patients with one or more colorectao lesion detected

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with one or more colorectal lesions detected during endocytoscopy will be included in the study. The rest of the inclusion and exclusion criteria are as described.

You may qualify if:

  • Patients who have at least one colorectal lesion detected during endocytoscopy
  • Consent obtained for the study

You may not qualify if:

  • lesions lacking high-quality images;
  • Inflammatory bowel disease, familial adenomatous polyposis and other special diseases;
  • Submucosal tumors;
  • Pathological diagnosis of inflammatory polyps, Peutz-Jeghers polyps, juvenile polyps, lymphoma and other special pathological types.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

The First Hospital of Jilin University

Changchun, Jilin, 130021, China

Location

Meihekou Central Hospital

Meihekou, Jilin, 135000, China

Location

Shandong Second Provincial General Hospital

Jinan, Shandong, 250000, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Histological specimens obtained after endoscopic or surgical treatment of colorectal lesions

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

Diagnosis, Computer-Assisted

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

Diagnosis

Study Officials

  • Hong Xu, Docror

    The First Hospital of Jilin University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Head of Gastroenterology and Endoscopy Center, Principal Investigator, Clinical Professor

Study Record Dates

First Submitted

January 20, 2025

First Posted

January 24, 2025

Study Start

February 5, 2025

Primary Completion

December 29, 2025

Study Completion

December 29, 2025

Last Updated

April 13, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations